Codexis Refinances Debt With $60M Trinity Capital Term Loan
CDXS sits 16% above its 52-week low of $0.958.
Summary
Codexis signed a $60 million senior secured term loan with Trinity Capital and drew $42.5 million up front to retire its Innovatus Life Sciences debt, which would have started amortizing in March 2027. Post-closing debt outstanding is $42.5 million, and the new facility carries 48 months of interest-only payments before a 12-month amortization begins November 2030. For a company with a roughly $120 million market cap, pushing principal repayment out four years removes near-term cash pressure and supports the ECO Synthesis platform build-out in siRNA manufacturing. Trinity is the lender here, not a party whose own thesis changes materially. The 8-K with the full loan and security agreement terms is the next filing to check for covenants and tranche conditions.
At the time of this announcement, CDXS was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.6M. The 52-week trading range was $0.96 to $2.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.